Related Experiment Video

Updated: Jun 28, 2026

Purification of Transcripts and Metabolites from Drosophila Heads
12:49

Purification of Transcripts and Metabolites from Drosophila Heads

Published on: March 15, 2013

21.8K

Are we missing a trick by not exploiting fruit flies in inflammation-led drug discovery for neurodegeneration?

Ray Price1, Miguel Ramirez-Moreno1, Amber Cooper1

  • 1Faculty of Natural and Environmental Sciences, University of Southampton, Southampton, UK.

Expert Opinion on Drug Discovery
|May 15, 2025
PubMed
Abstract

Insights

Fruit fly models offer a novel approach to Alzheimer's disease (AD) research by exploring inflammation. This powerful tool can accelerate the discovery of new anti-inflammatory drugs for AD therapeutics.

Area of Science:

  • Neuroscience
  • Immunology
  • Genetics

Background:

  • Alzheimer's disease (AD) presents a significant challenge with limited treatments.
  • Existing Drosophila models focus on Tau and amyloid beta toxicity, neglecting inflammation.
  • Innate immune pathways are conserved between flies and mammals, making Drosophila relevant for studying neuroinflammation.

Purpose of the Study:

  • To highlight the relevance of Drosophila in studying neuroinflammatory processes in AD.
  • To explore the use of fly models for screening anti-inflammatory compounds.
  • To investigate immune-related genetic factors in AD.

Main Methods:

  • Utilizing Drosophila melanogaster as a model organism.
  • Investigating glial activation, systemic inflammation, and gut-brain axis interactions.
  • Screening for anti-inflammatory compounds and dissecting immune-related genetic factors.

Main Results:

  • Drosophila models can effectively study neuroinflammation relevant to AD.
  • Fly models enable the screening of potential anti-inflammatory drugs.
  • Immune modulation in Drosophila can accelerate therapeutic strategy identification.

Conclusions:

  • Drosophila is an underutilized tool for inflammation-led drug discovery in AD.
  • Integrating immune modulation in Drosophila pipelines can speed up the identification of novel therapeutics.
  • Exploiting Drosophila for inflammation research may bridge fundamental science and translational medicine for AD.
Keywords:
Alzheimer’sDrosophiladisease pathogenesisdrug discoveryinflammationinnate immunityneurodegenerationneuroinflammation

More Related Videos

A Drosophila In Vivo Injury Model for Studying Neuroregeneration in the Peripheral and Central Nervous System09:55

A Drosophila In Vivo Injury Model for Studying Neuroregeneration in the Peripheral and Central Nervous System

Published on: May 5, 2018

9.7K
In Vivo Forward Genetic Screen to Identify Novel Neuroprotective Genes in Drosophila melanogaster10:00

In Vivo Forward Genetic Screen to Identify Novel Neuroprotective Genes in Drosophila melanogaster

Published on: July 11, 2019

9.3K

Related Concept Videos

Neurochemical Transmission: Sites of Drug Action01:26

Neurochemical Transmission: Sites of Drug Action

Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...